Dwight A. Bellinger
University of North Carolina at Chapel Hill
77 Papers
1.3K Citations
Dwight A. Bellinger is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Factor IX & Von Willebrand factor. The author has an hindex of 39, co-authored 77 publications. Previous affiliations of Dwight A. Bellinger include University of Pennsylvania & Salk Institute for Biological Studies.
Chat about Author
Papers
Long-term correction of canine hemophilia b by gene transfer of blood coagulation factor ix mediated by adeno-associated viral vector
Roland W. Herzog,Edmund Y Yang,Linda B. Couto,J. Nathan Hagstrom,Dan Elwell,Paul A. Fields,Melissa Burton,Dwight A. Bellinger,Marjorie S. Read,Kenneth M. Brinkhous,Gregory M. Podsakoff,Timothy C. Nichols,Gary J. Kurtzman,Katherine A. High,Katherine A. High +14 more
TL;DR: Using an adeno-associated viral vector, sustained expression of factor IX is demonstrated in a large-animal model at levels that would have a therapeutic effect in humans (up to 70 ng/ml, adequate to achieve phenotypic correction, in an animal injected with 8.5 × 1012 vector particles/kg).
623
Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
Richard O. Snyder,Carol H. Miao,Leonard Meuse,Julie Tubb,Brian A. Donahue,Hui Feng Lin,Darrel W. Stafford,Salil Patel,Arthur R. Thompson,Timothy C. Nichols,Marjorie S. Read,Dwight A. Bellinger,Kenneth M. Brinkhous,Mark A. Kay +13 more
TL;DR: Constitutive expression of factor IX was observed, which resulted in the correction of the bleeding disorder over a period of over 17 months in mice, and as a preclinical model for gene therapy, recombinant adeno-associated viral vectors containing the human or canine factor IX cDNAs were infused into the livers of murine and canine models of hemophilia B.
480
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
Jane D. Mount,Roland W. Herzog,D. Michael Tillson,Susan A. Goodman,Nancy Robinson,Mark L. McCleland,Dwight A. Bellinger,Timothy C. Nichols,Valder R. Arruda,Clinton D. Lothrop,Katherine A. High +10 more
TL;DR: Hemophilia B is an X-linked coagulopathy caused by absence of functional coagulation factor IX (FIX), and hepatic AAV gene transfer can result in sustained therapeutic expression in a large animal model characterized by increased risk of a neutralizing anti-FIX response.
382
In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs
Mark A. Kay,Steven S. Rothenberg,Charles N. Landen,Dwight A. Bellinger,Frances Leland,Carol Toman,Milton J. Finegold,Arthur R. Thompson,Marjorie S. Read,Kenneth M. Brinkhous,Savio L. C. Woo +10 more
TL;DR: Long-term treatment of hemophilia B patients may be feasible by direct hepatic gene therapy in vivo by the direct infusion of recombinant retroviral vectors into the portal vasculature, which results in the persistent expression of exogenous genes.
354
Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia
Paul E. Monahan,Richard Jude Samulski,J. Tazelaar,Xiao Xiao,Timothy C. Nichols,Dwight A. Bellinger,Marjorie S. Read,Christopher E. Walsh +7 more
TL;DR: This first large animal study suggests that intramuscular gene delivery using rAAV vectors is safe and supports continued development of this approach for gene therapy of human diseases, including hemophilia B.
222